The CPS is a better comparison to the total [89Zr]Zr-durvalumab tumor uptake than the Tumor Proportion Score (TPS), which is routinely used in clinical practice in NSCLC tumors and only includes PD-L1 expression on the tumor cells.20 CPS was demonstrated before to be equally predictive for immunotherapy efficacy, and in cases of TPS negative tumors even more predictive as compared with TPS.20 21 PD-L1 expression levels were divided into three categories: <1%, 1–49% and ≥50%. The gene discussed is CD274; the disease is non-small cell lung carcinoma.